The Elsevier Office of Continuing Medical Education, Elsevier and In Vivo Academy appreciate your participation in the webinar. For us to better assess the effectiveness of this activity and identify your ongoing educational needs, please complete this form.

*
*
*
*
*
*
*
*
*
*
PoorFairGoodVery goodExcellent
List the advantages and limitations of endpoints used in clinical trials, and be able to explain the reasons why it may be appropriate to consider endpoints other than OS when assessing data from clinical trials on NHL
Interpret common statistical concepts relating to diagnosis and treatment and infer how statistical data apply in their clinical practice
Appraise the information to be gained from the results of particular clinical trials based on the endpoints used
Communicate expected outcomes of therapy based on results of clinical studies.
*
NeverRarelySometimesMost of the timeAlwaysN/A
Consider endpoints other than overall survival as appropriate indicators of treatment efficacy
Clearly communicate to patients the significance of clinical trial results and the meaning of endpoints achieved in the context of the patient’s disease state and effect on the quality of life and survival
Make members of the healthcare team aware of the benefits and possible outcomes as indicated by clinical trial results so communication with patients by all team members is consistent
*
NeverRarelySometimesMost of the timeAlwaysN/A
Consider endpoints other than overall survival as appropriate indicators of treatment efficacy
Clearly communicate to patients the significance of clinical trial results and the meaning of endpoints achieved in the context of the patient’s disease state and effect on the quality of life and survival
Make members of the healthcare team aware of the benefits and possible outcomes as indicated by clinical trial results so communication with patients by all team members is consistent
*
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Overall, the activity met my learning needs
The information presented was without promotional or commercial bias
The content provided a fair and balanced coverage of the topic
Was scientifically rigorous and evidence based
Provided appropriate and effective opportunities for active learning (e.g., discussion, Q&A)
The quality of the educational process was satisfactory and appropriate
Promoted improvements or quality in health care
The information provided with regard to faculty financial relationships met my needs for disclosure
The speakers were knowledgeable and presented the information clearly
The format of the discussion was relevant and enhanced my knowledge of the subject
*
PoorFairGoodVery goodExcellent
Prof. John F. Seymour
Prof. Tim Illidge
Prof. James O. Armitage
*
*

Attestation on time spent on activity:

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Elsevier awards 1.5 contact hours toward CNE for this activity.

*